Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Akero Therapeutics, Inc.: Certificate of incorporation was amended and restated in its entirety.
- Change
- charter amendment
Exact text from the filing
the Company’s certificate of incorporation, as in effect immediately prior to the Effective Time, was amended and restated in its entirety to be in the form of Annex II to the Merger Agreement
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Akero Therapeutics, Inc.: Bylaws were amended and restated in their entirety to conform to the bylaws of Merger Sub.
- Change
- bylaw amendment
Exact text from the filing
the Company’s bylaws, as in effect immediately prior to the Effective Time, were amended and restated in their entirety to conform to the bylaws of Merger Sub
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Akero Therapeutics, Inc. underwent a change of control involving Novo Nordisk A/S for $54.00 per share in cash plus contingent value rights (closed 2025-12-09).
- Action
- change of control
- Counterparty
- Novo Nordisk A/S
- Consideration
- $54.00 per share in cash plus contingent value rights
- Closing
- 2025-12-09
Exact text from the filing
prior to the Effective Time (other than Excluded Shares and Dissenting Shares) was automatically cancelled and converted into the right to receive (i) cash in an amount equal to $54.00, without interest thereon and subject to any applicable tax withholdings (the “ Closing Consideration ”) and (ii) one contractual contingent value right (a “ CVR ”) representing
View on SEC.gov